HSPA5 and plasma cell myeloma: In patients with myeloma bone disease, i.e. osteolytic bone lesions, we found a trend to higher GRP78 protein levels in RRMM patients compared to NDMM patients (median 4.0 ng/mL vs. 2.7 ng/mL).